Dougherty & Co Upgrades Echelon (ELON) to Buy; Broadening Utility Customer Base and Potential for Upside
Get Alerts ELON Hot Sheet
Price: $21.88 --0%
Rating Summary:
4 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Dougherty & Co upgraded Echelon (NASDAQ: ELON) from Neutral to Buy. PT increased from $10 to $12.
Dougherty analyst says, "We increased our multiple from 2.0x FY12 EV/S based on the company’s broader utility customer base, increasing global opportunities, and potential for upside. The company’s new strategy to aggressively pursue sales (see note dated February 11, 2011) appears to be working. We continue to believe ELON can reach pro forma profitability in FY12. Our model calls for a pro forma profit of $0.02, which may prove conservative."
For more ratings news on Echelon click here and for the rating history of Echelon click here.
Shares of Echelon closed at $8.80 yesterday.
Dougherty analyst says, "We increased our multiple from 2.0x FY12 EV/S based on the company’s broader utility customer base, increasing global opportunities, and potential for upside. The company’s new strategy to aggressively pursue sales (see note dated February 11, 2011) appears to be working. We continue to believe ELON can reach pro forma profitability in FY12. Our model calls for a pro forma profit of $0.02, which may prove conservative."
For more ratings news on Echelon click here and for the rating history of Echelon click here.
Shares of Echelon closed at $8.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
- CIBC Upgrades PRO REIT (PRV-U:CN) to Outperformer
- Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share